Skip to main content
Premium Trial:

Request an Annual Quote

CollabRx, Alacris Partner on Cancer Sequencing Project

NEW YORK (GenomeWeb News) – CollabRx, a San Francisco-based personalized cancer research services firm, today said that it has initiated a cancer sequencing project in collaboration with Alacris Pharmaceuticals.

The company said that the firms will work together on the TREAT 1000 project, which will sequence 1,000 genomes of people with cancer. It said that the project will "create a compendium of cancer genome information that will inform future research and treatment."

CollabRx has been piloting its CollabRx One services program over the past year. The program uses a variety of genomic technologies for gene expression, SNP analysis, and copy number variation to analyze biopsies of tumors. The firm then uses bioinformatics and systems biology methods to link specific cancers to relevant therapies, thereby providing physicians with information they can use to tailor a treatment plan to individual patients.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.